Get the Stockscreener App
1.22
0.81%
-0.01
After Hours:
1.24
0.02
+1.64%
Quince Therapeutics Inc stock is traded at $1.22, with a volume of 721.06K.
It is down -0.81% in the last 24 hours and up +39.43% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$1.23
Open:
$1.24
24h Volume:
721.06K
Relative Volume:
0.08
Market Cap:
$19.89M
Revenue:
-
Net Income/Loss:
$-83.98M
P/E Ratio:
-0.0914
EPS:
-13.3519
Net Cash Flow:
$-41.78M
1W Performance:
-0.81%
1M Performance:
+39.43%
6M Performance:
-92.33%
1Y Performance:
-88.38%
1-Day Range:
$1.22
$1.29
1-Week Range:
$1.18
$1.34
52-Week Range:
$0.80
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.22 | 20.05M | 0 | -83.98M | -41.78M | -13.35 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80 - MSN
MSN Money - MSN
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics Regains Nasdaq Bid Compliance Amid Valuation Risk - The Globe and Mail
Quince Therapeutics (QNCX) restores bid compliance but still below $50M MVLS - Stock Titan
Large reverse split, director election on deck at Quince Therapeutics (QNCX) meeting - Stock Titan
SEC Form DEFA14A filed by Quince Therapeutics Inc. - Quantisnow
Quince Therapeutics settles $16.4M debt with $5.5M payment - MSN
Quince Therapeutics (QNCX) price target decreased by 21.74% to 6.12 - MSN
Why did QNCX stock plummet over 90% today? - MSN
Quince Therapeutics Appoints June Bray to Board - The Globe and Mail
Quince Therapeutics appoints June Bray to board of directors By Investing.com - Investing.com Australia
Quince Therapeutics appoints June Bray to board of directors - Investing.com
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
Quince Therapeutics, Inc. Appoints June Bray as Class I Director and to Nominating & Governance Committee, Audit Committee, and Compensation Committee, Effective April 22, 2026 - marketscreener.com
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics (QNCX) Stock: Worth Entering? (-6.93%) 2026-04-20Top Breakouts - Cổng thông tin điện tử Tỉnh Sơn La
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Quince Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Form PRE 14AOther preliminary proxy statements - ADVFN
Quince Therapeutics Inc. (NASDAQ: QNCX)Share Price - intelligentinvestor.com.au
Earnings Beat: Should I hold or sell Quince Therapeutics Inc now2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Treasury Yields: Whats Quince Therapeutics Incs historical returnMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Opening: Can Quince Therapeutics Inc sustain its profitabilityM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Quince Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
QNCX: Lead asset failed in Phase 3, triggering strategic review and raising going concern risks - TradingView
Phase 3 miss leaves Quince Therapeutics (QNCX) chasing reverse merger path - Stock Titan
Quince Therapeutics Announces 1-for-10 Reverse Stock Split - The Globe and Mail
Quince Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 13th, 2026 - Moomoo
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday - Investing.com Australia
Quince Therapeutics, Inc. Files Form 8-K Announcing Certificate of Amendment and Company Details - Minichart
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday By Investing.com - Investing.com South Africa
Quince Therapeutics (QNCX) enacts 1-for-10 reverse split, 16.3M shares post-split - Stock Titan
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):